7XP Stock Overview
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 0/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.27 |
| 52 Week High | US$21.80 |
| 52 Week Low | US$10.04 |
| Beta | 0.79 |
| 1 Month Change | 10.86% |
| 3 Month Change | 18.95% |
| 1 Year Change | -10.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7XP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.9% | 0.9% | -1.0% |
| 1Y | -10.2% | -27.7% | 2.0% |
Return vs Industry: 7XP exceeded the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: 7XP underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| 7XP volatility | |
|---|---|
| 7XP Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7XP has not had significant price volatility in the past 3 months.
Volatility Over Time: 7XP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| 7XP fundamental statistics | |
|---|---|
| Market cap | €4.68b |
| Earnings (TTM) | €972.56m |
| Revenue (TTM) | €5.90b |
4.8x
P/E Ratio0.8x
P/S RatioIs 7XP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7XP income statement (TTM) | |
|---|---|
| Revenue | US$6.35b |
| Cost of Revenue | US$2.61b |
| Gross Profit | US$3.74b |
| Other Expenses | US$2.69b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.07 |
| Gross Margin | 58.93% |
| Net Profit Margin | 16.50% |
| Debt/Equity Ratio | -12,758.6% |
How did 7XP perform over the long term?
See historical performance and comparison